People with rare, severe autoimmune diseases often live for years with progressive, disabling conditions managed by chronic immunosuppression that rarely addresses the underlying cause. Kyverna is developing an autologous CAR T-cell therapy designed to deliver a deep immune reset by broadly depleting pathogenic B cells, followed by repopulation with naïve, non-pathogenic B cells and normalization of T-cell function and cytokine profiles. This approach has the potential to enable durable remissions and discontinuation of background immunosuppressive therapies after a single infusion. The company’s pipeline is focused on neuroimmunology, with lead programs in generalized myasthenia gravis and stiff person syndrome. Warner Biddle, CEO of Kyverna Therapeutics, discusses the company’s B cell–targeting cell therapy platform, the range of autoimmune diseases it aims to address, and its next-generation therapies in development.
Stay Connected
Sign up for updates straight to your inbox.